别名 前列腺素E受体EP3亚型、EP3、lnc003875 + [8] |
简介 Receptor for prostaglandin E2 (PGE2) (PubMed:8307176, PubMed:7883006, PubMed:8117308, PubMed:8135729, PubMed:7981210). The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium (PubMed:7883006, PubMed:8117308, PubMed:8135729, PubMed:7981210). Required for normal development of fever in response to pyrinogens, including IL1B, prostaglandin E2 and bacterial lipopolysaccharide (LPS). Required for normal potentiation of platelet aggregation by prostaglandin E2, and thus plays a role in the regulation of blood coagulation. Required for increased HCO3(-) secretion in the duodenum in response to mucosal acidification, and thereby contributes to the protection of the mucosa against acid-induced ulceration. Not required for normal kidney function, normal urine volume and osmolality (By similarity). |
作用机制 EP2激动剂 [+1] |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 墨西哥 |
首次获批日期1985-01-01 |
作用机制 EP3激动剂 [+1] |
在研适应症 |
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-06-11 |
申办/合作机构- |
开始日期2023-05-25 |
开始日期2022-08-09 |